Publications by authors named "Holger Hebart"

Claim this Profile
M
MRD-guided zanubrutinib, venetoclax, and obinutuzumab in relapsed CLL: primary end point analysis from the CLL2-BZAG trial.
Moritz Fürstenau, Sandra Robrecht, Christof Schneider, Eugen Tausch, Adam Giza, Holger Hebart

Blood· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ibrutinib in Early-Stage Chronic Lymphocytic Leukemia: The Randomized, Placebo-Controlled, Double-Blind, Phase III CLL12 Trial.
Petra Langerbeins, Sandra Robrecht, Pascal Nieper, Paula Cramer, Moritz Fürstenau, Holger Hebart

J Clin Oncol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Guidelines of Onkopedia: What Is New? Locally Advanced Rectal Cancer.
Ralf-Dieter Hofheinz, Dirk Arnold, Markus Borner, Wolfgang Eisterer, Gunnar Folprecht, Holger Hebart

Oncol Res Treat· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impaired SARS-CoV-2-Specific CD8+ T Cells After Infection or Vaccination but Robust Hybrid T Cell Immunity in Patients with Multiple Myeloma.
Khalid Shoumariyeh, Benedikt Csernalabics, Elahe Salimi Alizei, Matthias Reinscheid, Sebastian Giese, Holger Hebart

Vaccines (Basel)· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Management and outcome of patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era - analysis of the European LeukemiaNet Blast Phase Registry.
Annamaria Brioli, Elza Lomaia, Christian Fabisch, Tomasz Sacha, Hana Klamova, Holger Hebart

Leukemia· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combined germline and somatic human FADD mutations cause autoimmune lymphoproliferative syndrome.
Olivier Pellé, Solange Moreno, Myriam Ricarda Lorenz, Quentin Riller, Marita Fuehrer, Holger F Hebart

J Allergy Clin Immunol· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Abnormal biomarkers predict complex FAS or FADD defects missed by exome sequencing.
Anne Rensing-Ehl, Myriam Ricarda Lorenz, Marita Führer, Wolfgang Willenbacher, Ella Willenbacher, Holger Hebart

J Allergy Clin Immunol· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations.
Moritz Fürstenau, Yvonne J Thus, Sandra Robrecht, Clemens H M Mellink, Anne-Marie van der Kevie-Kersemaekers, Holger Hebart

Blood· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia.
Barbara Eichhorst, Carsten U Niemann, Arnon P Kater, Moritz Fürstenau, Julia von Tresckow, Holger Hebart

N Engl J Med· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Tirabrutinib and Idelalisib With or Without Obinutuzumab in Relapsed Chronic Lymphocytic Leukemia.
Nadine Kutsch, Christian Pallasch, Thomas Decker, Holger Hebart, Kai Uwe Chow

Hemasphere· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preinfection laboratory parameters may predict COVID-19 severity in tumor patients.
Alexander Kiani, Romina Roesch, Clemens M Wendtner, Frank Kullmann, Thomas Kubin, Holger Hebart

Cancer Med· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nintedanib plus mFOLFOX6 as second-line treatment of metastatic, chemorefractory colorectal cancer: The randomised, placebo-controlled, phase II TRICC-C study (AIO-KRK-0111).
Thomas J Ettrich, Lukas Perkhofer, Thomas Decker, Ralf-Dieter Hofheinz, Volker Heinemann, Holger F Hebart

Int J Cancer· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
Kinetics of Renal Function during Induction in Newly Diagnosed Multiple Myeloma: Results of Two Prospective Studies by the German Myeloma Study Group DSMM.
Friederike Bachmann, Martin Schreder, Monika Engelhardt, Christian Langer, Denise Wolleschak, Holger Hebart

Cancers (Basel)· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical characteristics and outcome of multiple myeloma patients with concomitant COVID-19 at Comprehensive Cancer Centers in Germany.
Monika Engelhardt, Khalid Shoumariyeh, Amelie Rösner, Gabriele Ihorst, Francesca Biavasco, Holger Hebart

Haematologica· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase III randomized, double-blind study of paclitaxel with and without everolimus in patients with advanced gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC).
Sylvie Lorenzen, Jorge Riera Knorrenschild, Claudia Pauligk, Susanna Hegewisch-Becker, Jörg Seraphin, Holger Hebart

Int J Cancer· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HOVON110/ReBeL Study: Results of the Phase I Part of a Randomized Phase I/II Study of Lenalidomide, Rituximab With or Without Bendamustine in Patients With Relapsed/Refractory Follicular Lymphoma.
Wendy B C Stevens, Katerina Bakunina, Marloes Cuijpers, Martine Chamuleau, Aart Beeker, Holger Hebart

Hemasphere· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Allogeneic transplantation in multiple myeloma: long-term follow-up and cytogenetic subgroup analysis.
Stefan Knop, Monika Engelhardt, Peter Liebisch, Christoph Meisner, Ernst Holler, Holger Hebart

Leukemia· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV.
Christian Michel, Andreas Burchert, Andreas Hochhaus, Susanne Saussele, Andreas Neubauer, Holger Hebart

Haematologica· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjuvant Chemotherapy of Locally Advanced Colon Cancer: Final Results of a Randomized Trial Comparing 5-Fluorouracil and Folinic Acid with Folfiri.
Stephan Paschke, Holger Hebart, Roland Goeb, Ludger Staib, Ullrich Fleck

Visc Med· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prospective Observational Cohort Study to Describe the Use of Panitumumab in Combination with Chemotherapy in Real-World Clinical Practice for Patients with Wild-Type RAS mCRC.
Holger Hebart, Michael Kiehl, Jiri Tomasek, Tibor Csoszi, Reija Koukakis

Adv Ther· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial.
Paula Cramer, Julia von Tresckow, Jasmin Bahlo, Sandra Robrecht, Petra Langerbeins, Holger Hebart

Lancet Oncol· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tolerability and efficacy of deferasirox in patients with transfusional iron overload: results from a German 2-year non-interventional study.
Florian Nolte, Holger Nückel, Burkhard Schmidt, Thomas Geer, Oleg Rubanov, Holger Hebart

J Cancer Res Clin Oncol· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CNS progression during vinblastine or targeted therapies for high-risk relapsed ALK-positive anaplastic large cell lymphoma: A case series.
Stephanie Ruf, Holger Hebart, Lisa Lyngsie Hjalgrim, Edita Kabickova, Peter Lang

Pediatr Blood Cancer· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II study of bortezomib, cyclophosphamide and dexamethasone as induction therapy in multiple myeloma: DSMM XI trial.
Hermann Einsele, Monika Engelhardt, Christoph Tapprich, Jürgen Müller, Peter Liebisch, Holger Hebart

Br J Haematol· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study.
Anna Maria Fink, Jasmin Bahlo, Sandra Robrecht, Othman Al-Sawaf, Ali Aldaoud, Holger Hebart

Lancet Haematol· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis